Form 4: Summit Therapeutics CEO Reports Stock Transaction
Insider Transaction (Form 4)
Mahkam Zanganeh, Co-Chief Executive Officer, a Director and 10% owner of Summit Therapeutics Inc., reported multiple transactions in common stock on November 16, 2026.
Summary
- Option exercise/conversion: acquired 500,000 Common Stock at $1.06 ($530,000) on November 16, 2026; holds 531,000 after (Direct).
- Option exercise/conversion: disposed of 500,000 Stock Option (right to buy) on November 16, 2026; holds 800,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Mahkam Zanganeh — Director, Officer (Co-Chief Executive Officer), 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-11-16 | Option exercise/conversion | Common Stock | 500,000 | $1 | $530.0K | 531,000 |
| 2026-11-16 | Option exercise/conversion | Stock Option (right to buy) | 500,000 | — | — | 800,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-11-16 | Option exercise/conversion (500,000 shares) |
| 2026-11-16 | Option exercise/conversion (500,000 shares) |
Keywords
insider transaction, Form 4, SMMT, Summit Therapeutics Inc., neutral, Mahkam Zanganeh
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.